Literature DB >> 18948059

Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.

Philipp Wolf1, Ursula Elsässer-Beile.   

Abstract

The pathogenic bacterium Pseudomonas aeruginosa has the ability to cause severe acute and chronic infections in humans. Pseudomonas exotoxin A (PE) is the most toxic virulence factor of this bacterium. It has ADP-ribosylation activity and decisively affects the protein synthesis of the host cells. The cytotoxic pathways of PE have been elucidated, and it could be shown that PE uses several molecular strategies developed under evolutionary pressure for effective killing. Interestingly, a medical benefit from this molecule has also been ascertained in recent years and several PE-based immunotoxins have been constructed and tested in preclinical and clinical trials against different cancers. In these molecules, the enzymatic active domain of PE is specifically targeted to tumor-related antigens. This review describes the current knowledge about the cytotoxic pathways of PE. Additionally, it summarizes preclinical and clinical trials of PE-based immunotoxins and furthermore discusses current problems and answers with these agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948059     DOI: 10.1016/j.ijmm.2008.08.003

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.658


  50 in total

Review 1.  Who's really in control: microbial regulation of protein trafficking in the epithelium.

Authors:  Matthew R Hendricks; Jennifer M Bomberger
Journal:  Am J Physiol Cell Physiol       Date:  2013-10-16       Impact factor: 4.249

2.  Pseudomonas aeruginosa and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes.

Authors:  Andreas Weber; Corinna Zimmermann; Anne K Mausberg; Thomas Dehmel; Bernd C Kieseier; Hans-Peter Hartung; Harald H Hofstetter
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

Review 3.  Pouring salt on a wound: Pseudomonas aeruginosa virulence factors alter Na+ and Cl- flux in the lung.

Authors:  Alicia E Ballok; George A O'Toole
Journal:  J Bacteriol       Date:  2013-07-08       Impact factor: 3.490

4.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

Review 5.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

6.  Targeted Toxin Gene Therapy Of Breast Cancer Stem Cells Using CXCR1 Promoter And bFGF 5'UTR.

Authors:  Cobra Moradian; Fatemeh Rahbarizadeh
Journal:  Onco Targets Ther       Date:  2019-10-25       Impact factor: 4.147

7.  Occurrence, antimicrobial susceptibility, and pathogenic factors of Pseudomonas aeruginosa in canine clinical samples.

Authors:  Jasmine Hattab; Francesco Mosca; Cristina Esmeralda Di Francesco; Giovanni Aste; Giuseppe Marruchella; Pierluigi Guardiani; Pietro Giorgio Tiscar
Journal:  Vet World       Date:  2021-04-23

8.  Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary.

Authors:  Lori L Tortorella; Nina H Pipalia; Sushmita Mukherjee; Ira Pastan; David Fitzgerald; Frederick R Maxfield
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

9.  Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.

Authors:  Sangsu Park; Minh Quan Nguyen; Huynh Kim Khanh Ta; Minh Tan Nguyen; Gunsup Lee; Chong Jai Kim; Yeon Jin Jang; Han Choe
Journal:  Int J Mol Sci       Date:  2021-06-17       Impact factor: 6.208

10.  Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Authors:  Rafal Zielinski; Ilya Lyakhov; Amy Jacobs; Oleg Chertov; Gabriela Kramer-Marek; Nicholas Francella; Andrew Stephen; Robert Fisher; Robert Blumenthal; Jacek Capala
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.